The provided text is an excerpt from a Form 10-Q, a quarterly report filed by Pfizer Inc. with the Securities and Exchange Commission (SEC). The report details the company's financial performance for the second quarter and first six months of 2024, including revenues, costs and expenses, net income, and cash flows. It also discusses significant accounting policies, critical accounting estimates, and assumptions, as well as legal proceedings, contingencies, and commitments. In addition, the report provides information about Pfizer's product developments and the regulatory actions taken by the FDA and other regulatory authorities.